NCT03611348 is a Phase 2, PHASE3 clinical trial of Latanoprost in Vitiligo, sponsored by Sohag University.

Who is sponsoring NCT03611348?

NCT03611348 is sponsored by Sohag University.

What drugs are being tested in NCT03611348?

Interventions in NCT03611348: Latanoprost, Microneedling.

Is NCT03611348 still recruiting?

NCT03611348 is currently status unknown. Last updated 28 August 2018.

Last reviewed 2018-08-28 · How we verify

NCT03611348

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Microneedling and Latanoprost in Acrofacial Vitiligo

Status unknown Phase 2, PHASE3 Last updated 28 August 2018

What this trial tests

Phase 2, PHASE3 trial testing Latanoprost in Vitiligo in 70 participants. Status unknown.

Timeline

1 September 2018

Primary endpoint
1 September 2019

1 December 2019

Quick facts

Lead sponsor	Sohag University
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	1 September 2018
Primary completion	1 September 2019
Estimated completion	1 December 2019

Drugs / interventions tested

Latanoprost (LATANOPROST) — full drug profile →
Microneedling

Conditions studied

Vitiligo — all drugs for Vitiligo →

Sponsor

Sohag University

Who can join

18 and older, any sex, with Vitiligo. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare efficacy of topical latanoprost preceded by microneedling versus topical latanoprost alone in treatment of acrofacial vitiligo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Latanoprost

Trials testing the same drug.

NCT06666855 — A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China · Phase 3 · active not recruiting
NCT06239324 — Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser · Phase 1, PHASE2 · recruiting
NCT04811326 — Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation · Phase 4 · unknown
NCT03762369 — A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 · Phase 3 · unknown
NCT04178863 — CATS Tonometer IOP Reduction Latanoprost Verses Timolol · Phase 4 · unknown

Other recruiting trials for Vitiligo

Currently open trials in the same condition.

NCT07153666 — A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo · recruiting
NCT07267273 — Betamethasone Phonophoresis For Vitiligo · NA · recruiting
NCT07232238 — TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients · active not recruiting
NCT07532330 — Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo · NA · active not recruiting
NCT07357870 — A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo · Phase 1 · recruiting

Other Sohag University trials

Trials by the same sponsor.

NCT07119905 — Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patie · not yet recruiting
NCT07512219 — Comparison Between Greater Occipital Nerve Block and Pulsed Radiofrequency in the Management of Chronic Migraine · NA · not yet recruiting
NCT07519694 — Comparative Study Between Different Additives to Lidocaine 2٪ for Peribulbar Block in Vitreoretinal Surgery · NA · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
NCT07523386 — Compartive Study Between Cannulated Screw and Kws in Fixation of Distal Radius · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03611348 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sohag University
Last refreshed: 28 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03611348.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing